Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Marco Davila"'
Autor:
Yannick Bulliard, Bin Yu, Emiliano Roselli, Gongbo Li, Hiroshi Kotani, Kristen Spitler, Kayla Reid, Nhan Tu, Sae Bom Lee, Justin Boucher, Frederick Locke, Marco Davila
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/4dd86bd562ed433290c362dd6582299f
Autor:
Joseph Pidala, Francisca Beato, Jongphil Kim, Brian Betts, Heather Jim, Elizabeth Sagatys, John E. Levine, James L.M. Ferrara, Umut Ozbek, Ernesto Ayala, Marco Davila, Hugo F. Fernandez, Teresa Field, Mohamed A. Kharfan-Dabaja, Divis Khaira, Farhad Khimani, Frederick L. Locke, Asmita Mishra, Michael Nieder, Taiga Nishihori, Lia Perez, Marcie Riches, Claudio Anasetti
Publikováno v:
Haematologica, Vol 103, Iss 3 (2018)
T-helper 1 and T-helper 17 lymphocytes mediate acute graft-versus-host disease (GvHD). Interleukin 12 is critical for T-helper 1 differentiation and interleukin 23 for T-helper 17 maintenance. Interleukin 12 and 23 are heterodimeric cytokines that sh
Externí odkaz:
https://doaj.org/article/2c93c615953a4fe3a8f3072e166b06e9
Autor:
Brian C. Betts, Joseph Pidala, Jongphil Kim, Asmita Mishra, Taiga Nishihori, Lia Perez, Jose Leonel Ochoa-Bayona, Farhad Khimani, Kelly Walton, Ryan Bookout, Michael Nieder, Divis K. Khaira, Marco Davila, Melissa Alsina, Teresa Field, Ernesto Ayala, Frederick L. Locke, Marcie Riches, Mohamed Kharfan-Dabaja, Hugo Fernandez, Claudio Anasetti
Publikováno v:
Haematologica, Vol 102, Iss 5 (2017)
Graft-versus-host disease (GvHD) remains a major cause of transplant-related mortality. Interleukin-2 (IL-2) plus sirolimus (SIR) synergistically reduces acute GvHD in rodents and promotes regulatory T cells. This phase II trial tested the hypothesis
Externí odkaz:
https://doaj.org/article/59183ba5b9594f8b90b610eba3642511
Autor:
Robert Wenham, Marco Davila, Daniel Abate-Daga, Melissa McGettigan, Xuefeng Wang, Theresa Boyle, Pamela Garzone, Amit Kumar, Jose Conejo-Garcia
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Maria Lia Palomba, Matthew G. Mei, Paolo F. Caimi, Matthew Cortese, Marco Davila, Greg Yadnik, Nestor Huang, David Mou, Martin Oft, Paul-Joseph Aspuria, Anita Mehta-Damani, Navneet Ratti, Naiyer Rizvi, Alex Azrilevich, Ran Reshef
Publikováno v:
Cancer Research. 83:CT125-CT125
Background: Chimeric antigen receptor T cell therapy (CAR T) has demonstrated remarkable clinical efficacy in hematological malignancies. However, compromised T cell effector function, proliferation, and persistence can limit CAR T from reaching thei
Autor:
Johannes F. Fahrmann, Neeraj Y. Saini, Chang Chia-Chi, Ehsan Irajizad, Paolo Strati, Ranjit Nair, Luis E. Fayad, Sairah Ahmed, Hun Ju Lee, Swaminathan Iyer, Raphael Steiner, Jody Vykoukal, Ranran Wu, Jennifer B. Dennison, Loretta Nastoupil, Preetesh Jain, Michael Wang, Michael Green, Jason Westin, Viktoria Blumenberg, Marco Davila, Richard Champlin, Elizabeth J. Shpall, Partow Kebriaei, Christopher R. Flowers, Michael Jain, Robert Jenq, Christoph K. Stein-Thoeringer, Marion Subklewe, Sattva S. Neelapu, Sam Hanash
Publikováno v:
Cell reports. Medicine. 3(11)
Anti-CD19 chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory (r/r) large B cell lymphoma (LBCL) results in durable response in only a subset of patients. MYC overexpression in LBCL tumors is associated with poor response to tre
Autor:
Neeraj Y. Saini, David M. Swoboda, Uri Greenbaum, Jungsheng Ma, Romil Patel, Kartik Devashish, Kaberi Das, Mark R. Tanner, Paolo Strati, Ranjit Nair, Luis E. Fayad, Sairah Ahmed, Hun Ju Lee, Swaminathan Iyer, Raphael Steiner, Nitin Jain, Loretta Nastoupil, Sanam Loghavi, Guilin Tang, Preetesh Jain, Michael Wang, Jason Westin, Michael R. Green, David Sallman, Eric Padron, Marco Davila, Frederick L. Locke, Richard Champlin, Elizabeth Shpall, Partow Kebriaei, Christopher R. Flowers, Michael Jain, Feng Wang, Andrew Futreal, Nancy Gillis, Sattva S. Neelapu, Koichi Takahashi
To explore the role of clonal hematopoiesis (CH) on chimeric antigen receptor (CAR) T-cell therapy outcomes, we performed targeted deep-sequencing on 114 large B-cell lymphoma patients treated with anti-CD19 CAR T-cells. We detected CH in 42 (36.8%)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cde9269890494bf3bc2d3b2e2bfe255a
https://doi.org/10.1101/2021.09.28.461858
https://doi.org/10.1101/2021.09.28.461858
Autor:
Farhad, Khimani, Peter, Ranspach, Hany, Elmariah, Jongphil, Kim, Junmin, Whiting, Taiga, Nishihori, Frederick L, Locke, Ariel, Perez Perez, Erin, Dean, Asmita, Mishra, Lia, Perez, Aleksandr, Lazaryan, Michael D, Jain, Michael, Nieder, Hein, Liu, Rawan, Faramand, Doris, Hansen, Melissa, Alsina, Leonel, Ochoa, Marco, Davila, Claudio, Anasetti, Joseph, Pidala, Nelli, Bejanyan
Publikováno v:
Transplantation and cellular therapy. 27(11)
Post-transplantation cyclophosphamide (PTCy) is being increasingly used for graft-versus-host disease (GVHD) prophylaxis after allogeneic hematopoietic cell transplantation (allo-HCT) across various donor types. However, immune reconstitution and inf
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S257
Autor:
Marco Dávila
Without the faintest idea about what was happening and against his will, Enrique Ortega crossed a portal that took him to Terros, a world convincingly similar to our nineteenth-century planet, but with a minor significant difference: the existence of